Your browser is no longer supported. Please, upgrade your browser.
DURECT Corporation
Index- P/E- EPS (ttm)-0.17 Insider Own0.10% Shs Outstand227.50M Perf Week-13.27%
Market Cap154.67M Forward P/E- EPS next Y-0.16 Insider Trans9.50% Shs Float224.16M Perf Month-32.19%
Income-38.10M PEG- EPS next Q-0.05 Inst Own52.50% Short Float3.04% Perf Quarter-43.60%
Sales8.90M P/S17.38 EPS this Y40.10% Inst Trans-0.08% Short Ratio9.27 Perf Half Y-55.41%
Book/sh0.28 P/B2.36 EPS next Y5.60% ROA- Target Price6.00 Perf Year-70.67%
Cash/sh0.34 P/C1.91 EPS next 5Y15.00% ROE- 52W Range0.67 - 2.95 Perf YTD-33.07%
Dividend- P/FCF- EPS past 5Y17.80% ROI-20.70% 52W High-77.61% Beta1.31
Dividend %- Quick Ratio8.90 Sales past 5Y9.50% Gross Margin83.20% 52W Low-1.51% ATR0.07
Employees79 Current Ratio9.10 Sales Q/Q22.20% Oper. Margin- RSI (14)22.28 Volatility8.85% 8.05%
OptionableYes Debt/Eq0.32 EPS Q/Q4.70% Profit Margin- Rel Volume1.25 Prev Close0.68
ShortableYes LT Debt/Eq0.32 EarningsNov 02 AMC Payout- Avg Volume735.84K Price0.66
Recom1.70 SMA20-23.80% SMA50-32.22% SMA200-51.16% Volume921,445 Change-2.93%
Oct-30-20Initiated Chardan Capital Markets Buy $7
Oct-12-20Initiated ROTH Capital Buy
Jul-31-20Initiated Oppenheimer Outperform $7
Jan-31-20Initiated B. Riley FBR Buy $5
Nov-18-19Resumed Cantor Fitzgerald Overweight
Sep-06-19Initiated Cantor Fitzgerald Overweight $5
Mar-06-18Upgrade H.C. Wainwright Neutral → Buy $3.50
Oct-20-17Reiterated Laidlaw Buy $3 → $2
Oct-20-17Downgrade Stifel Buy → Hold $3 → $0.90
Oct-20-17Downgrade H.C. Wainwright Buy → Neutral
Jul-12-17Upgrade Stifel Hold → Buy $1.25 → $3
Feb-28-17Resumed H.C. Wainwright Buy $3
Apr-25-16Initiated Rodman & Renshaw Buy $4
May-01-15Reiterated Stifel Buy $1.50 → $2.50
May-01-15Reiterated Cantor Fitzgerald Buy $2.50 → $3
Mar-25-13Initiated Stifel Buy $3
Nov-01-12Downgrade C.K. Cooper Buy → Hold $3
Aug-17-12Initiated C.K. Cooper Buy $3
Jun-23-09Initiated Caris & Company Buy $5
Mar-26-09Initiated Wedbush Morgan Hold
Jan-13-22 10:00AM  
Jan-06-22 04:05PM  
Dec-22-21 07:30AM  
Dec-14-21 09:00AM  
Nov-29-21 09:00AM  
Nov-12-21 09:00AM  
Nov-10-21 09:00AM  
Nov-08-21 09:00AM  
Nov-07-21 07:45AM  
Nov-02-21 06:15PM  
Oct-26-21 09:00AM  
Oct-25-21 03:01PM  
Oct-07-21 09:00AM  
Sep-23-21 09:00AM  
Sep-15-21 09:00AM  
Sep-07-21 09:00AM  
Aug-09-21 05:29AM  
Jul-29-21 07:25PM  
Jul-22-21 08:30AM  
Jul-14-21 04:30PM  
Jun-25-21 09:37AM  
Jun-23-21 09:00AM  
Jun-09-21 09:00AM  
May-04-21 07:45PM  
Apr-27-21 08:30AM  
Mar-09-21 09:00AM  
Mar-04-21 05:31PM  
Mar-03-21 06:02PM  
Feb-04-21 09:18AM  
Feb-03-21 04:01PM  
Feb-02-21 08:28AM  
Jan-25-21 08:30AM  
Jan-05-21 08:30AM  
Jan-04-21 08:30AM  
Dec-21-20 08:30AM  
Dec-16-20 08:30AM  
Dec-09-20 01:33PM  
Dec-07-20 11:15AM  
Nov-13-20 09:00AM  
Nov-10-20 08:30AM  
Nov-02-20 11:31PM  
Oct-27-20 08:30AM  
Oct-26-20 04:30PM  
Oct-05-20 08:30AM  
Sep-30-20 04:53PM  
Sep-23-20 08:30AM  
Sep-22-20 08:30AM  
Sep-10-20 08:30AM  
Aug-27-20 08:30AM  
Aug-26-20 04:30PM  
Aug-05-20 03:31PM  
Aug-04-20 01:00AM  
Aug-03-20 06:35PM  
Jul-28-20 08:30AM  
Jul-07-20 07:35AM  
Jul-01-20 08:30AM  
Jun-29-20 09:00AM  
Jun-26-20 05:15PM  
Jun-11-20 02:45PM  
May-28-20 09:00AM  
May-26-20 08:30AM  
May-20-20 10:04AM  
May-12-20 03:00PM  
May-11-20 06:55PM  
May-04-20 05:00PM  
Apr-28-20 12:33PM  
Mar-24-20 04:18PM  
Mar-03-20 04:05PM  
Feb-26-20 07:30AM  
Feb-10-20 08:05AM  
Jan-31-20 11:14AM  
Jan-17-20 08:19AM  
Jan-16-20 02:38PM  
Jan-02-20 05:28PM  
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops DUR-928, an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid homeostasis, inflammation, and cell survival, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Gilead Sciences, Inc. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BENITO SIMON XDirectorDec 07Buy1.0220,00020,360105,000Dec 09 01:35 PM
Joice Judy RSr. VP Operations & Corp QAMay 14Option Exercise0.7660,13745,90794,969May 17 09:37 PM
Joice Judy RSr. VP Operations & Corp QAMay 14Sale1.7260,137103,68234,832May 17 09:37 PM